EGFR and colorectal carcinoma: In addition, Mizukami et al. found that high FGF9 expression in CRC patients is associated with anti-EGFR therapies resistance and FGF9 amplification is frequently observed in more aggressive CRC tumors (Mizukami et al., 2017).